<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508677</url>
  </required_header>
  <id_info>
    <org_study_id>P060104</org_study_id>
    <nct_id>NCT00508677</nct_id>
  </id_info>
  <brief_title>Mazindol in Children With ADHD : Open-label, Efficacy, Safety and Pharmacokinetic Pilot Trial</brief_title>
  <acronym>MAZDAH</acronym>
  <official_title>Mazindol in Children With Attention Deficit Hyperactivity Disorder Design Study to Explore the Effectiveness, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Orally Administered Doses of Mazindol.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective pilot trial will evaluate the efficacy, safety, tolerability and&#xD;
      pharmacokinetic (PK) and pharmacodynamic (PD) properties of mazindol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most common intervention for Attention Deficit Hyperactivity Disorder (ADHD) is&#xD;
      pharmacological treatment with methylphenidate (MPH). Effects of MPH on ADHD symptoms in&#xD;
      children is extremely well-informed. Mazindol is a psychostimulant and a wake-promoter agent&#xD;
      which may have similar actions to MPH in the central nervous system. However, there is no&#xD;
      record of the effects, safety, tolerability of Mazindol in children with ADHD. Mazindol (dose&#xD;
      0.5 or 1.0 mg/day) should prove to be useful in the treatment of ADHD symptoms in children.&#xD;
      Based on clinical assessments and serum concentrations after oral administration of mazindol&#xD;
      to children (6-12 years) with ADHD, this prospective pilot trial will evaluate the efficacy,&#xD;
      safety, tolerability and pharmacokinetic (PK) and pharmacodynamic (PD) properties of&#xD;
      mazindol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">24</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <eligibility>
    <study_pop>
      <textblock>
        childrens&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects can be boys or girls&#xD;
&#xD;
          -  Subjects must be aged between 6 to 12 years,&#xD;
&#xD;
          -  Tanner 1 ou 2&#xD;
&#xD;
          -  Subjects with a diagnosis of ADHD according to the Diagnostic and Statistical Manual&#xD;
             of Mental Diseases, Fourth Edition (DSM-IV) criteria&#xD;
&#xD;
          -  ADHD-RS score of ≥ 31 as determined by investigator at screening visit.&#xD;
&#xD;
          -  Drug free including psychostimulants (10 days before the screening visit)&#xD;
&#xD;
          -  Informed Consent Form signed by the subject and both parents&#xD;
&#xD;
          -  Healthy on the basis of a physical examination, medical history and the results of&#xD;
             blood hematology tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically unstable psychiatric condition including, but not limited to the&#xD;
             following: acute mood disorder, bipolar disorder, obsessive-compulsive disorder (OCD),&#xD;
             autism or Asperger…&#xD;
&#xD;
          -  Sleep Disorders including narcolepsy, hypersomnia (according to International&#xD;
             Classification of Sleep Disorders (ICSD) criteria&#xD;
&#xD;
          -  Chronic diseases (e.g. asthma…)&#xD;
&#xD;
          -  Current eating disorder (e.g. bulimia, anorexia nervosa) or history of an eating&#xD;
             disorder during infancy&#xD;
&#xD;
          -  Mental retardation (IQ &lt; 80)&#xD;
&#xD;
          -  Hyperthyroidism&#xD;
&#xD;
          -  Subjects with history of seizures, glaucoma or familial hypertension&#xD;
&#xD;
          -  Heart pathologies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric KONOFAL, MD-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Robert Debre</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>July 26, 2007</study_first_submitted>
  <study_first_submitted_qc>July 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2007</study_first_posted>
  <last_update_submitted>September 30, 2009</last_update_submitted>
  <last_update_submitted_qc>September 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Yannick VACHER</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>Mazindol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

